



JCO2 Rec'd PCT/PTC

06 JUN 2005

PATENTS

ATTY. DOCKET NO. 18377-0059

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brian G. Condie, et al.

Serial No.: 10/529,115

Filed: March 24, 2005

For: Compositions and Methods for
Enrichment of Neural Stem Cells
Using Ceramide Analogs

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached three pages Form PTO-1449, "List of Information Disclosed by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of the listed items are enclosed.

Pursuant to the Office's waiver of the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national phase patent applications filed after June 30, 2003, no copy of any cited U.S. patent or U.S. patent application publication is being provided herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 2, 2005.

Elizabeth Cary Miller
Elizabeth Cary Miller - Reg. No. 54,708

U.S.S.N.: 10/529,115
Filed: March 24, 2005
INFORMATION DISCLOSURE STATEMENT

As this Information Disclosure Statement is being submitted prior to the issuance of a first office action, no fees are believed to be due.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


Elizabeth Cary Miller
Reg. No. 54,708

Date: June 2, 2005

SUTHERLAND ASBILL & BRENNAN LLP
999 Peachtree Street, NE
Atlanta, Georgia 30309-3996
Telephone: (404) 853-8000
Facsimile: (404) 853-8806



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/529,115
Filing Date	March 24, 2005
First Named Inventor	Brian G. Condie
Art Unit	
Examiner Name	
Attorney Docket Number	18377-0059

Sheet 1 of 3

*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/529,115
				Filing Date	March 24, 2005
				First Named Inventor	Brian G. Condie
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	18377-0059
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		BAIN, et al., 1995, "Embryonic Stem Cells Express Neuronal Properties <i>in vitro</i> ," <i>Dev. Biology</i> , 168:342-357.			
		BIEBERICH, et al., 2001, "Regulation of Apoptosis During Neuronal Differentiation by Ceramide and b-Series Complex Gangliosides," <i>The Journal of Biological Chemistry</i> , 276:44396-44404.			
		BIEBERICH, et al., 1999, "Differential Effects of Glycolipid Biosynthesis Inhibitors on Ceramide-Induced Cell Death in Neuroblastoma Cells," <i>Journal of Neurochemistry</i> , 72:1040-1049.			
		BLASCHKE, et al., 1998, "Programmed Cell Death is a Universal Feature of Embryonic and Postnatal Neuroproliferative Regions throughout the Central Nervous System," <i>The Journal of Comparative Neurology</i> , 396:39-50.			
		BLASCHKE, et al., 1996, "Widespread Programmed Cell Death in Proliferative and Postmitotic Regions of the Fetal Cerebral Cortex," <i>Development</i> , 122:1165-1174.			
		BRUGG, et al., 1996, "Ceramide Induces Apoptosis in Cultured Mesencephalic Neurons," <i>Journal of Neurochemistry</i> , 66:733-739.			
		BRUSTLE, et al., 1997, "In Vitro-Generated Neural Precursors Participate in Mammalian Brain Development", <i>Proc. Natl. Acad. Sci. USA</i> , 94:14809-14814.			
		CARPENTER, et al., 2001, "Enrichment of Neurons and Neural Precursors from Human Embryonic Stem Cells", <i>Exper. Neuro.</i> , 172:383-397.			
		CASACCIA-BONNEFIL, et al., 1996, "Death of Oligodendrocytes Mediated by the Interaction of Nerve Growth Factor with its Receptor p75," <i>Nature</i> , 383:716-719.			
		CHUN, Jerold, 2000, "Cell Death, DNA Breaks and Possible Rearrangements: An Alternative View," <i>Trends in Neuroscience</i> , 23:407-408.			
		DECRAENE, et al., 2002, "Identification of Genes Involved in Ceramide-Dependent Neuronal Apoptosis using cDNA Arrays," <i>Genome Biol.</i> , 3(8)research 0042.1-0042.22.			
		ESDAR, et al., 2001, "Differentiation-Associated Apoptosis of Neural Stem Cells is Effected by Bcl-2 Overexpression: Impact on Cell Lineage Determination", <i>Eur. J. Cell Biol.</i> , 80:539-553.			
		FRAICHARD, et al., 1995, "In Vitro Differentiation of Embryonic Stem Cells into Glial Cells and Functional Neurons", <i>J. Cell Sci.</i> , 108:3181-3188.			
		FURUYA, et al., 1998, "Ceramide and Its Interconvertible Metabolite Sphingosine Function as Indispensable Lipid Factors Involved in Survival and Dendritic Differentiation of Cerebellar Purkinje Cells," <i>Journal of Neurochemistry</i> , 71:366-377.			
		HARTFIELD, et al., 1997, "Ceramide Induces Apoptosis in PC12 cells," <i>FEBS Letters</i> , 401:148-152.			
		HERGET, et al., 2000, "Production of Ceramides Causes Apoptosis During Early Neural Differentiation <i>in Vitro</i> , <i>The Journal of Biological Chemistry</i> , 275:30344-30354.			
		IRIE, et al., 1998, "Application of Exogenous Ceramide to Cultured Rat Spinal Motoneurons Promotes Survival or Death by Regulation of Apoptosis Depending on its Concentrations," <i>Journal of Neuroscience Research</i> , 54:475-485.			
		ITO, et al., 1995, "Ceramide Prevents Neuronal Programmed Cell Death Induced by Nerve Growth Factor Deprivation," <i>Journal of Neurochemistry</i> , 65:463-466.			
		JAFFRÉZOU, et al., 1998, "Positive Feedback Control of Neural Sphingomyelinase Activity by Ceramide," <i>FASEB</i> , 12:999-1006.			
		KAWASAKI, et al., 2002, "Generation of Dopaminergic Neurons and Pigmented Epithelia from Primate ES Cells by Stromal Cell-Derived Inducing Activity", <i>Proc. Natl. Acad. Sci. USA</i> , 99(3):1580-1585.			
		KAWASAKI, et al., 2000, "Induction of Midbrain Dopaminergic Neurons from ES Cells by Stromal Cell-Derived Inducing Activity", <i>Neuron</i> , 28:31-40.			
		KIM, et al., 2002, "Dopamine Neurons Derived from Embryonic Stem Cells Function in an Animal Model of Parkinson's Disease", <i>Nature</i> 418:50-56.			
		LI, et al., 1998, "Generation of Purified Neural Precursors from Embryonic Stem Cells by Lineage Selection", <i>Current Biol.</i> 8:971-974.			
		LIU, et al., 2000, "Hypoxic Preconditioning Protects Cultured Neurons against Hypoxic stress via TNF- α and Ceramide," <i>Am. J. Physiol. Cell Physiol.</i> , 278:C144-C153.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/529,115
Filing Date	March 24, 2005
First Named Inventor	Brian G. Condie
Art Unit	
Examiner Name	
Attorney Docket Number	18377-0059

Sheet	3	of	3
-------	---	----	---

[illegible]

**Examiner
Signature**

Date
Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.